In the phase III ClarIDHy trial, ivosidenib, small molecule inhibitor of mutant IDH1, improved PFS over a placebo (2.7 versus 1.4 months, respectively) in IDH1-mutant chemotherapy-refractory CCA, but no improvement in the median OS was observed [91··]. Here, IDH1 is linked to cholangiocarcinoma.